McCallum et al. analysed data from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) trial and found that patients suffering from heart failure with reduced ejection fraction (HFrEF) who had elevated NT-proBNP serum concentrations were at significantly higher risk of developing a > 40% eGFR decline (HR = 2.62, 95%CI 1.62-4.23) (60). The gene discussed is NPPB; the disease is heart failure.